Long-Term Treatment of Metastatic Colorectal Cancer with Panitumumab

Colorectal cancer is one of the leading causes of cancer-related deaths worldwide. More than 30% patients present with metastases at diagnoses and will require systemic chemotherapy. In recent years many anti-EGFR targets have been developed. Among them, panitumumab, a fully human IgG2 monoclonal an...

Descripción completa

Detalles Bibliográficos
Autores principales: López-Gómez, Miriam, Merino, María, Casado, Enrique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2012
Materias:
Expert Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3296490/
https://www.ncbi.nlm.nih.gov/pubmed/22408376
http://dx.doi.org/10.4137/CMO.S5055
_version_ 1782225738253991936
author López-Gómez, Miriam
Merino, María
Casado, Enrique
author_facet López-Gómez, Miriam
Merino, María
Casado, Enrique
author_sort López-Gómez, Miriam
collection PubMed
description Colorectal cancer is one of the leading causes of cancer-related deaths worldwide. More than 30% patients present with metastases at diagnoses and will require systemic chemotherapy. In recent years many anti-EGFR targets have been developed. Among them, panitumumab, a fully human IgG2 monoclonal antibody has shown important benefits in the treatment of this disease.
format Online
Article
Text
id pubmed-3296490
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Libertas Academica
record_format MEDLINE/PubMed
spelling pubmed-32964902012-03-09 Long-Term Treatment of Metastatic Colorectal Cancer with Panitumumab López-Gómez, Miriam Merino, María Casado, Enrique Clin Med Insights Oncol Expert Review Colorectal cancer is one of the leading causes of cancer-related deaths worldwide. More than 30% patients present with metastases at diagnoses and will require systemic chemotherapy. In recent years many anti-EGFR targets have been developed. Among them, panitumumab, a fully human IgG2 monoclonal antibody has shown important benefits in the treatment of this disease. Libertas Academica 2012-02-28 /pmc/articles/PMC3296490/ /pubmed/22408376 http://dx.doi.org/10.4137/CMO.S5055 Text en © 2012 the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.
spellingShingle Expert Review
López-Gómez, Miriam
Merino, María
Casado, Enrique
Long-Term Treatment of Metastatic Colorectal Cancer with Panitumumab
title Long-Term Treatment of Metastatic Colorectal Cancer with Panitumumab
title_full Long-Term Treatment of Metastatic Colorectal Cancer with Panitumumab
title_fullStr Long-Term Treatment of Metastatic Colorectal Cancer with Panitumumab
title_full_unstemmed Long-Term Treatment of Metastatic Colorectal Cancer with Panitumumab
title_short Long-Term Treatment of Metastatic Colorectal Cancer with Panitumumab
title_sort long-term treatment of metastatic colorectal cancer with panitumumab
topic Expert Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3296490/
https://www.ncbi.nlm.nih.gov/pubmed/22408376
http://dx.doi.org/10.4137/CMO.S5055
work_keys_str_mv AT lopezgomezmiriam longtermtreatmentofmetastaticcolorectalcancerwithpanitumumab
AT merinomaria longtermtreatmentofmetastaticcolorectalcancerwithpanitumumab
AT casadoenrique longtermtreatmentofmetastaticcolorectalcancerwithpanitumumab

Ejemplares similares